Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Katja C. Weisel

University Medical Center Hamburg-Eppendorf

Germany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Articles (17)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (14)

Francesca Gay

Associate Professor

University of Turin

ITALY

View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES

View details

Jan Krönke

Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

ROBERTO MINA

Assistant professor

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY

View details

Gordon Cook

University of Leeds

UNITED KINGDOM

View details

Juan Du

Prof

Shanghai Jiao Tong University

CHINA

View details

Peter Bannas

University Medical Center Hamburg-Eppendorf

GERMANY

View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Benjamin Derman

Assistant Professor

University of Chicago

UNITED STATES

View details

Sagar Lonial

UNITED STATES

View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Michael E. O'Dwyer

Professor of Haematology

National University of Ireland Galway

IRELAND

View details

Marc S. Raab

University Hospital Heidelberg

GERMANY

View details

Nico Gagelmann

University Medical Center Hamburg-Eppendorf

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katja C. Weisel

Research Interests

Make your next move.

Explore related searches

Articles (17)

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis

A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies

Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells

T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

Collaborators (14)

Francesca Gay

Ola Landgren

Jan Krönke

ROBERTO MINA

Gordon Cook

Juan Du

Peter Bannas

Robert Orlowski

Benjamin Derman

Sagar Lonial

Saad Usmani

Michael E. O'Dwyer

Marc S. Raab

Nico Gagelmann

Make your next move.